Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 5/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MME | P08473 | 3/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941976 | 0.80 | TSHR (0.39) | ECE1MMEACECPA1ACE2 | |
| SCHEMBL13575644 | 0.80 | TSHR (0.39) | ECE1MMEACECPA1ACE2 | |
| SCHEMBL13575688 | 0.80 | TSHR (0.39) | ECE1MMEACECPA1ACE2 | |
| SCHEMBL13318045 | 0.79 | ECE1 (0.56) | ECE1TDP1MMEACECPA1 | |
| SCHEMBL21566764 | 0.78 | ECE1 (0.46) | ECE1TDP1CASP1ALDH1A1LMNA | |
| SCHEMBL13450167 | 0.78 | ALDH1A1 (0.39) | ECE1TDP1MMEACECPA1 | |
| SCHEMBL4400595 | 0.77 | ECE1 (0.37) | ECE1ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL22952374 | 0.77 | ECE1 (0.44) | ECE1TDP1MMEACECPA1 | |
| SCHEMBL19703836 | 0.77 | ECE1 (0.44) | ECE1TDP1MMECASP1ALDH1A1 | |
| SCHEMBL13461384 | 0.77 | CA1 (0.47) | ECE1TDP1MMELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265459-A1 | Compositions Useful in Treatment of Spinal Muscular Atrophy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-08-24 | — | — | US | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265459-A1 | Compositions Useful in Treatment of Spinal Muscular Atrophy | SMN1; SMN2, SRP68, HNRNPH1 | ECE1 4376/4885TDP1 917/4885MME 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.